Baseline Ad5 serostatus does not predict Ad5-HIV vaccine-induced expansion of Ad-specific CD4+ T-cells

The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear. We find Ad5 serostatus does not predict Ad5-specific CD4(+) T-cell frequency, and no durable significant differences in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutnick, Natalie A., Carnathan, Diane G., Dubey, Sheri A., Cox, Kara, Kierstead, Lisa, Ratcliffe, Sarah J., Robertson, Michael N., Casimiro, Danilo R., Ertl, Hildegund C.J., Betts, Michael R.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723179/
https://www.ncbi.nlm.nih.gov/pubmed/19620962
http://dx.doi.org/10.1038/nm.1989
Descripción
Sumario:The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear. We find Ad5 serostatus does not predict Ad5-specific CD4(+) T-cell frequency, and no durable significant differences in Ad5-specific CD4(+) T-cells between Ad5-seropositive and seronegative subjects were observed following vaccination. These findings indicate no causative role for Ad5-specific CD4(+) T-cells in increasing HIV-1 susceptibility in the STEP trial.

Ejemplares similares